Bipolar I Disorder

Clinical picture

• Mania presents with elevated or irritable mood, decreased need for sleep, pressured speech, and goal-directed overactivity lasting a week or more.
• Insight collapses during mania; patients experience grandiose plans as genuine capability and resist treatment as unwanted interference.
• Psychosis occurs in more than half of manic episodes and is typically grandiose or persecutory and mood-congruent in content.
• Depressive episodes outnumber manic ones roughly three to one over time and account for most disability and most suicide risk.
• Mixed features, meaning agitated depression with racing thoughts, are common and carry elevated suicide and switching risk.
• Between episodes many patients retain subsyndromal symptoms and measurable deficits in attention, memory, and executive function.

Criteria snapshot

• Requires at least one manic episode: abnormally elevated, expansive, or irritable mood with increased activity for a week or any hospitalization.
• Three additional symptoms are required, or four if mood is only irritable, spanning grandiosity, reduced sleep need, pressured speech, and risky behavior.
• Mania must cause marked impairment, require hospitalization, or include psychotic features; hypomania by definition does none of these.
• Depressive and hypomanic episodes are extremely common but are not required for the diagnosis once a manic episode has occurred.
• Specify current episode type, severity, psychotic features, and course specifiers including rapid cycling of four or more episodes yearly.

Neurobiology

• Heritability is roughly 60 to 85 percent, among the highest in psychiatry, with substantial polygenic overlap with schizophrenia and depression.
• Dopaminergic hyperactivity underlies mania while subsequent receptor downregulation may drive the depressive switch in the dysregulation model.
• Amygdala hyperreactivity with reduced ventral prefrontal modulation impairs emotional regulation across manic, depressed, and euthymic states.
• Mitochondrial dysfunction, abnormal intracellular calcium signaling, and altered GSK-3 activity are among lithium's putative molecular targets.
• Circadian and social rhythm instability is central; sleep loss reliably precipitates mania and functions as both a symptom and a trigger.
• White matter hyperintensities, progressive cognitive decline, and elevated cardiovascular mortality shorten lifespan by roughly 10 to 20 years.

Psychology

• Behavioral activation system dysregulation predicts manic response to goal attainment and to reward-relevant life events.
• Social zeitgeber theory holds that disrupted daily routines and sleep-wake schedules destabilize circadian rhythms and precipitate episodes.
• Hyperpositive self-appraisal and denial of illness drive medication discontinuation, which remains the leading proximate cause of relapse.
• Prodrome recognition, personalized early warning signs, and a rehearsed rapid action plan form the core psychoeducational target.
• High expressed emotion in families, particularly criticism and overinvolvement, predicts shorter time to relapse and worse functional outcome.

Differential & comorbidity

• Distinguish from schizoaffective disorder by whether psychosis persists two or more weeks in the absence of prominent mood symptoms.
• Rule out substance-induced mania, corticosteroid effects, hyperthyroidism, and antidepressant-induced switching before making the diagnosis.
• Borderline personality disorder shows mood shifts lasting hours, reactive to interpersonal triggers, without sustained reduction in sleep need.
• Substance use disorders co-occur in roughly 40 to 60 percent of patients, alongside anxiety disorders, ADHD, and metabolic syndrome.
• Lifetime suicide attempt rates approach 30 percent and mortality is many times the general population, peaking in mixed and depressive states.

Pharmacologic treatment

• Lithium 0.6-1.2 mEq/L remains first line and uniquely reduces suicide; monitor levels, renal function, thyroid, and serum calcium.
• Valproate 50-125 mcg/mL is useful for mixed states and rapid cycling but is teratogenic and contraindicated in pregnancy.
• Second-generation antipsychotics including quetiapine 400-800 mg/day, olanzapine, and aripiprazole treat acute mania within several days.
• For bipolar depression use quetiapine, lurasidone 20-120 mg/day, or olanzapine-fluoxetine rather than antidepressant monotherapy.
• Lamotrigine 100-200 mg/day prevents depressive relapse; titrate slowly across 6 weeks to reduce the risk of serious rash.

Psychotherapy

• Illness-focused psychoeducation across roughly 6 to 21 sessions reliably reduces relapse and improves medication adherence.
• IPSRT stabilizes sleep-wake and social routines and lengthens time to recurrence, particularly for depressive episodes.
• Family-focused therapy across about 21 sessions reduces relapse by lowering expressed emotion and improving communication skills.
• CBT targets residual depression and dysfunctional attitudes, with the largest effects seen early in the illness course.
• Psychotherapy is always adjunctive here; no evidence supports psychotherapy alone for the treatment of acute mania.

Adjunct options

• ECT is highly effective for refractory mania, mixed states, catatonia, and severe bipolar depression including during pregnancy.
• Enforce sleep regularity, avoid shift work and rapid time-zone travel, and treat comorbid substance use aggressively and early.
• Track with the YMRS, MADRS, and a daily mood chart; patient-kept charts often reveal seasonal and cyclic patterns.
• Baseline and periodic metabolic screening, ECG where indicated, and explicit pregnancy planning discussions are standard of care.
• Escalate to inpatient care for mania with psychosis, judgment impairment endangering finances or safety, or acute suicidality.

Clinical pearls

• One manic episode makes it Bipolar I forever, regardless of later depressions.
• Lithium is the only agent with consistent anti-suicide evidence.
• Sleep loss is both prodrome and cause of mania; protect it first.